Famous Patents
In 1608, Dutch eyeglass maker Hans Lipperhey filed the first patent for a working telescope. The patent was denied.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8389507 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands The present invention relates to compounds of formula I wherein R1, R2, R3, Ar, n and o are as defined herein and to their pharmaceutically acceptable active salts. Compounds of fo... | 03/05/2013 |
| 8361998 | Compounds and their use as IKACh blockers The invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, x and y are as defined herei... | 01/29/2013 |
| 8334282 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular... | 12/18/2012 |
| 8263583 | Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide This invention relates to the hydrochloride salt of 5-[3-{3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanamide or derived form thereof and its use as a medicament. ... | 09/11/2012 |
| 8247401 | P2Xreceptor antagonists for treatment of pain The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 | 08/21/2012 |
| 8207155 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders In one aspect, the invention relates to compounds which are useful as inhibitors of glycine type 1 transporter (GlyT1) activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders assoc... | 06/26/2012 |
| 8173631 | Cyclic amine compounds Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof ... | 05/08/2012 |
| 8080541 | Carbocyclic GlyT-1 receptor antagonists The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid additi... | 12/20/2011 |
| 7968534 | Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors The present invention is directed to a compound of formula (I): wherein Ar1, Ar2, Ar3, R1 and T are as defined herein, its preparation, pharmaceutical composition and uses as orexin 2 recept... | 06/28/2011 |
| 7932245 | Spirocyclopropyl amides and acids and their therapeutic applications The present invention relates to the use of compounds of formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection. ... | 04/26/2011 |
| 7919487 | Heteroaryl compounds This invention relates to compounds of formula (I): their compositions and methods of use thereof. The compounds (and compositions) are useful in modulating IL-12 production and processes mediated by IL-12. ... | 04/05/2011 |
| 7790707 | S1P receptor modulating compounds and use thereof The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl... | 09/07/2010 |
| 7772223 | Carboxamide derivatives as muscarinic receptor antagonists The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them. ... | 08/10/2010 |
| 7759335 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular... | 07/20/2010 |
| 7741316 | Pharmacological uses of azetidine derivatives A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 ... | 06/22/2010 |
| 7718642 | AIDS prophylactic lubricating composition A prophylactic lubricant composition for use during sexual relations, includes: a) lubricant effective to reduce friction, thereby reducing the rupture of blood vessels during sexual relations, b) an effective amou... | 05/18/2010 |
| 7696191 | Crystalline compound A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment... | 04/13/2010 |
| 7691841 | Azetidine derivatives as CCR-3 receptor antagonist Compounds of formula I in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condit... | 04/06/2010 |
| 7687489 | Agent for treatment of cerebral ischemic diseases A pharmaceutical composition for the treatment and/or prevention of cerebral ischemic diseases, which comprises two components, i.e. an astrocyte function-improving agent, preferably a compound represented by the formula (I): | 03/30/2010 |
| 7666860 | Melt-formulated, multi-particulate oral dosage form A melt-formulated, multiparticulate, oral dosage form containing clavulanic acid and/or at least one physiologically acceptable salt thereof and at least one sucrose fatty acid ester and optionally further physiologically acceptable auxiliary substances; a process f... | 02/23/2010 |
| 7544676 | Sulfamoyl benzamides and methods of their use Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or ligands of cannabinoid... | 06/09/2009 |
| 7494987 | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient An agent for preventing/treating respiratory diseases contains, as an active ingredient, a compound represented by following Formula (I): wherein A is a group represented by L-W [wherein L is a bond or CH2; and W... | 02/24/2009 |
| 7465719 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently:—O —C(═O)— or —C(═O)—O — or —C(═O)—; Cy is a cyclyl ... | 12/16/2008 |
| 7378399 | Avermectins substituted in the 4″ and 4′-positions having pesticidal properties What is described are a compound of the formula (I) Wherein A-B is —CH═CH— or —CH2—CH2—; n is 0 or 1; R1, is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl;... | 05/27/2008 |
| 7342135 | 3(4),7(8)-Bis(aminomethyl)bicyclo[4.3.0]nonane and a process for its preparation 3(4),7(8)-bis(aminomethyl)bicyclo[4.3.0]nonane and a process for its preparation, wherein bicyclo[4.3.0]nona-3,7-diene is reacted with synthesis gas in a homogeneous organic phase in the presence of transition metal compounds of Group VIII of the Periodic Table cont... | 03/11/2008 |
| 7291615 | Cyclic derivatives as modulators of chemokine receptor activity The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and ... | 11/06/2007 |
| 7288537 | Azetidine derivatives as CCR-3 receptor antagonists Compounds of formula I in free or salt form, wherein Ar, X, Y, R1, R2, R3, R5, m, n, p and q have the meanings as indicated in the specification, are useful for treatin... | 10/30/2007 |
| 7285565 | Benzamides and related inhibitors of factor Xa Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. ... | 10/23/2007 |
| 7259184 | Ion channel modulating compounds and uses thereof Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatme... | 08/21/2007 |
| 7256186 | Gamma secretase inhibitors This invention discloses novel gamma secretase inhibitors of the formula: wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 ... | 08/14/2007 |
| 7227035 | Bis-aryl sulfonamides Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls i... | 06/05/2007 |
| 7217705 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the tr... | 05/15/2007 |
| 7214701 | Active substance combinations having insecticidal and acaricdal properties The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising (a) compounds of the formula (I) ... | 05/08/2007 |
| 7208602 | Gamma secretase inhibitors This invention discloses novel gamma secretase inhibitors of the formula: wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 ... | 04/24/2007 |
| 7208524 | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R1 is a hydrogen atom or an optionally substituted lower alkyl group; | 04/24/2007 |
| 7148258 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity. ... | 12/12/2006 |
| 7132414 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—... | 11/07/2006 |
| 7105504 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the tr... | 09/12/2006 |
| 7105705 | Hyperforin derivatives, the use thereof and formulations containing them The use of the reduction products of hyperforin and adhyperforin, pharmaceutically acceptable salts or esters thereof, in the pharmaceutical and/or nutritional field, in particular in the treatment of depression and Alzheimer's disease. ... | 09/12/2006 |
| 7101895 | Cyclohexyl sulphone derivatives as gamma-secretase inhibitors Compounds of formula I: wherein Ar1 and Ar2 are optionally substituted aryl or heteroaryl, L is a bond, ═CH— or —(CHRa)n—, and X is SCN, SR1, S(O)R | 09/05/2006 |
